Format

Send to

Choose Destination
Neuroreport. 2010 Mar 31;21(5):390-4. doi: 10.1097/WNR.0b013e3283381a4e.

Glycine transporter inhibition reverses ketamine-induced working memory deficits.

Author information

1
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.

Abstract

Glycine transporter inhibitors have recently been reported to improve symptoms in patients with schizophrenia. Here we used acute ketamine in the nonhuman primate to test the effectiveness of the novel glycine transporter inhibitor, PF-3463275, in a model of cognitive dysfunction relevant to schizophrenia. PF-3463275 (0.01-0.17 mg/kg; subcutaneously) or a vehicle was given before the administration of ketamine (median dose of 1.0 mg/kg intramuscularly) or placebo (saline). Ketamine induced hallucinatory-like behaviors that were not reversed by PF-3463275. In contrast, all doses of PF-3463275 alleviated the deficit in spatial working memory induced by ketamine. Theses findings build upon those in patients by providing translational support for targeting glycine transporter in adjunctive treatment for cognitive dysfunction in schizophrenia.

PMID:
20186106
DOI:
10.1097/WNR.0b013e3283381a4e
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center